Immuneering Corporation (NASDAQ:IMRX) CEO Benjamin J. Zeskind Acquires 21,000 Shares

Immuneering Corporation (NASDAQ:IMRX) CEO Benjamin J. Zeskind acquired 21,000 shares of the firm’s stock in a transaction that occurred on Wednesday, June 18th. The stock was purchased at an average cost of $2.39 per share, with a total value of $50,190.00. Following the purchase, the chief executive officer now directly owns 2,302,852 shares in the company, valued at approximately $5,503,816.28. This trade represents a 0.92% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Immuneering Stock Down 7.6%

Shares of NASDAQ:IMRX opened at $2.56 on Friday. The firm has a fifty day moving average of $1.62 and a two-hundred day moving average of $1.75. The firm has a market capitalization of $92.13 million, a P/E ratio of -1.31 and a beta of 0.01. Immuneering Corporation has a 12-month low of $1.00 and a 12-month high of $3.83.

Immuneering (NASDAQ:IMRX) last issued its earnings results on Monday, May 5th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.01). Equities research analysts expect that Immuneering Corporation will post -1.86 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on IMRX shares. Oppenheimer decreased their price objective on shares of Immuneering from $25.00 to $21.00 and set an “outperform” rating for the company in a research note on Wednesday, May 7th. Needham & Company LLC reaffirmed a “buy” rating and issued a $9.00 price objective on shares of Immuneering in a research note on Wednesday. Chardan Capital reaffirmed a “buy” rating and issued a $13.00 price objective on shares of Immuneering in a research note on Wednesday. Finally, Mizuho raised their price objective on shares of Immuneering from $8.00 to $10.00 and gave the stock an “outperform” rating in a research note on Wednesday. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $13.25.

Institutional Investors Weigh In On Immuneering

A number of institutional investors have recently modified their holdings of the stock. Southport Management L.L.C. boosted its stake in shares of Immuneering by 4.9% during the 4th quarter. Southport Management L.L.C. now owns 215,000 shares of the company’s stock valued at $473,000 after buying an additional 10,000 shares during the period. Two Sigma Investments LP boosted its stake in shares of Immuneering by 25.0% during the 4th quarter. Two Sigma Investments LP now owns 50,557 shares of the company’s stock valued at $111,000 after buying an additional 10,126 shares during the period. Tang Capital Management LLC acquired a new stake in shares of Immuneering during the 4th quarter valued at $27,000. HighTower Advisors LLC boosted its stake in shares of Immuneering by 17.7% during the 1st quarter. HighTower Advisors LLC now owns 83,960 shares of the company’s stock valued at $128,000 after buying an additional 12,600 shares during the period. Finally, Jane Street Group LLC acquired a new stake in shares of Immuneering during the 1st quarter valued at $32,000. Institutional investors and hedge funds own 67.65% of the company’s stock.

About Immuneering

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.